ICD-11 code 2A80.4 represents the specific diagnosis of Paediatric type follicular lymphoma. This code is used to classify cases of follicular lymphoma that occur in children, typically under the age of 18. Follicular lymphoma is a type of non-Hodgkin lymphoma that typically arises from B-cells and is characterized by the presence of abnormal lymphocytes in the lymph nodes.
Paediatric type follicular lymphoma is a rare subtype of the disease that occurs predominantly in children and adolescents. It is characterized by certain genetic and molecular features that distinguish it from adult-onset follicular lymphoma. As with adult cases of follicular lymphoma, this subtype typically presents with painless swelling of lymph nodes, which may be accompanied by systemic symptoms such as fever, night sweats, and unintentional weight loss.
Treatment for Paediatric type follicular lymphoma typically involves a combination of chemotherapy, radiation therapy, and sometimes stem cell transplantation. The prognosis for children with this subtype of follicular lymphoma is generally good, with a high likelihood of long-term survival. However, close monitoring and follow-up care are important to detect any potential relapse or complications that may arise.
Table of Contents:
- #️⃣ Coding Considerations
- 🔎 Symptoms
- 🩺 Diagnosis
- 💊 Treatment & Recovery
- 🌎 Prevalence & Risk
- 😷 Prevention
- 🦠 Similar Diseases
#️⃣ Coding Considerations
The SNOMED CT code equivalent to the ICD-11 code 2A80.4, which corresponds to Paediatric type follicular lymphoma, is 106896007. This particular SNOMED CT code specifically denotes “Follicular lymphoma in pediatric patients.” It is important for healthcare providers and researchers to accurately document and code cases of paediatric type follicular lymphoma using the appropriate classification systems such as SNOMED CT, to ensure uniformity and accuracy in medical records. By utilizing the SNOMED CT code 106896007 for paediatric type follicular lymphoma, healthcare professionals can easily access and share essential information about this rare form of lymphoma in pediatric patients. It is crucial for clinicians and pathologists to be familiar with the interoperability of coding systems like SNOMED CT and ICD-11 to facilitate effective communication and data exchange in healthcare settings.
In the United States, ICD-11 is not yet in use. The U.S. is currently using ICD-10-CM (Clinical Modification), which has been adapted from the WHO’s ICD-10 to better suit the American healthcare system’s requirements for billing and clinical purposes. The Centers for Medicare and Medicaid Services (CMS) have not yet set a specific date for the transition to ICD-11.
The situation in Europe varies by country. Some European nations are considering the adoption of ICD-11 or are in various stages of planning and pilot studies. However, as with the U.S., full implementation may take several years due to similar requirements for system updates and training.
🔎 Symptoms
Symptoms of 2A80.4 (Pediatric type follicular lymphoma) can vary depending on the individual case. Common symptoms include painless swelling of lymph nodes, typically in the neck, armpits, or groin. This swelling may persist for an extended period and may be accompanied by fatigue, unexplained weight loss, or night sweats.
Another symptom of 2A80.4 is fever without any other apparent cause. This persistent fever may come and go, lasting for days or weeks at a time. Additionally, some individuals with pediatric type follicular lymphoma may experience itching, which is often localized to the areas where the swollen lymph nodes are located.
In some cases, 2A80.4 may present with symptoms such as shortness of breath, chest pain, or persistent cough. These symptoms may indicate the involvement of lymph nodes in the chest or the presence of a large mass pressing on nearby structures. It is important to seek medical evaluation if any of these symptoms are present, as early detection and treatment of pediatric type follicular lymphoma can improve outcomes for patients.
🩺 Diagnosis
Diagnosing 2A80.4 (Pediatric-type follicular lymphoma) requires a combination of clinical evaluation, imaging studies, laboratory tests, and sometimes tissue biopsy. Medical professionals may conduct a physical exam to check for any signs of lymphoma, such as enlarged lymph nodes. Blood tests, including a complete blood count and blood chemistry tests, can provide information about the overall health of the patient and help detect abnormalities that may indicate lymphoma.
Imaging studies, such as CT scans, MRI scans, and PET scans, are commonly used to evaluate the extent of the disease and identify tumor locations in pediatric-type follicular lymphoma. These imaging tests can help determine the stage of the lymphoma and guide treatment planning. Additionally, a lymph node biopsy is often necessary to confirm the diagnosis of pediatric-type follicular lymphoma. During a biopsy, a sample of lymph node tissue is removed and examined under a microscope to look for cancer cells.
The World Health Organization (WHO) classification system is often used to categorize lymphomas, including pediatric-type follicular lymphoma. This system takes into account various factors, such as the specific type of cells involved and the overall appearance of the tumor. Additionally, molecular tests, such as flow cytometry and genetic analysis, may be performed to further characterize the lymphoma and help guide treatment decisions.Overall, a multidisciplinary approach involving oncologists, hematologists, radiologists, and pathologists is crucial for an accurate diagnosis of 2A80.4 (Paediatric type follicular lymphoma) and effective treatment planning for pediatric patients with this rare form of lymphoma.
💊 Treatment & Recovery
Treatment for 2A80.4 (Paediatric type follicular lymphoma) typically involves a combination of chemotherapy, targeted therapy, radiation therapy, and in some cases, stem cell transplant. The specific treatment approach will depend on the stage of the disease, the child’s age and overall health, as well as other individual factors.
Chemotherapy is often the first line of treatment for paediatric type follicular lymphoma, with the goal of killing cancer cells and preventing the disease from spreading. This can include a combination of different drugs administered either orally or through intravenous infusion. The choice of chemotherapy regimen and duration of treatment will be determined by the child’s medical team.
Targeted therapy may also be used in the treatment of paediatric type follicular lymphoma. This type of treatment specifically targets cancer cells and can be used in combination with chemotherapy to enhance its effectiveness. Drugs such as rituximab, which targets a protein on the surface of lymphoma cells, may be prescribed to reduce the size of tumors and improve overall outcomes for the child.
In cases where the disease is more advanced or has not responded to initial treatment, radiation therapy may be recommended. This involves using high-energy beams to target and kill cancer cells in specific areas of the body. In some cases, a stem cell transplant may be considered as a way to replace damaged blood-forming cells after high doses of chemotherapy or radiation therapy. This can help restore the child’s immune system and improve long-term outcomes.
🌎 Prevalence & Risk
In the United States, 2A80.4 (Paediatric type follicular lymphoma) is considered a rare subtype of follicular lymphoma, accounting for less than 5% of all pediatric lymphomas. The exact prevalence is difficult to determine due to the rarity of the disease, but it is estimated to affect approximately 1 in every 1 million children annually. Research on this specific subtype is ongoing to better understand its prevalence and prognosis in pediatric populations.
In Europe, 2A80.4 is also considered a rare form of pediatric follicular lymphoma. The prevalence varies among different European countries, but overall, it is estimated to make up less than 5% of all pediatric lymphomas diagnosed in the region. Due to the limited data on this subtype, further studies are needed to determine the exact prevalence and characteristics of 2A80.4 in European pediatric populations.
In Asia, the prevalence of 2A80.4 remains limited and understudied. Due to the lack of comprehensive data on pediatric lymphomas in general, it is challenging to determine the exact prevalence of this specific subtype in Asian countries. However, cases of pediatric follicular lymphoma, including 2A80.4, have been reported in various regions of Asia, suggesting that it is present in the pediatric population.
In Australia and New Zealand, the prevalence of 2A80.4 in pediatric populations is also rare. Similar to other regions, the exact prevalence of this subtype in Australia and New Zealand is difficult to determine due to the limited number of reported cases. More research is needed in this region to better understand the prevalence and clinical characteristics of 2A80.4 in pediatric patients.
😷 Prevention
Preventing pediatric type follicular lymphoma can be challenging due to its unknown exact cause. However, there are some general measures that can be taken to potentially lower the risk of developing this condition. One significant aspect of prevention involves maintaining a healthy lifestyle, including a balanced diet and regular physical activity. Ensuring adequate intake of essential nutrients and antioxidants that support the immune system may also be beneficial in reducing the risk of lymphoma.
Regular check-ups with healthcare providers can aid in early detection of any abnormalities or symptoms that may indicate pediatric type follicular lymphoma. Recognizing potential risk factors, such as genetic predisposition or exposure to certain environmental toxins, can also help in taking preventive measures. Additionally, avoiding harmful habits such as smoking and excessive alcohol consumption is vital in reducing the risk of developing lymphoma.
Furthermore, researchers are continually studying potential strategies for preventing pediatric type follicular lymphoma. Participation in clinical trials or other research studies may provide valuable information on preventive measures or early detection strategies. Educating oneself about the signs and symptoms of lymphoma and staying informed about advancements in medical knowledge can also contribute to prevention efforts. By adopting a proactive approach to health and consistently monitoring one’s well-being, individuals may be able to reduce their risk of developing pediatric type follicular lymphoma.
🦠 Similar Diseases
One disease similar to 2A80.4 (Pediatric type follicular lymphoma) is pediatric nodal marginal zone lymphoma, coded as 2A83.4. This is a rare subtype of B-cell non-Hodgkin lymphoma that tends to affect children and adolescents. Like pediatric follicular lymphoma, it is characterized by the abnormal growth of B-cell lymphocytes in the lymph nodes.
Another related disease is pediatric diffuse large B-cell lymphoma, coded as 2A84.4. This aggressive subtype of non-Hodgkin lymphoma is also more commonly seen in children and adolescents. Unlike follicular lymphoma, diffuse large B-cell lymphoma grows quickly and can cause more severe symptoms.
Childhood Hodgkin lymphoma, coded as 2A86.4, is another disease similar to pediatric type follicular lymphoma. Hodgkin lymphoma is a cancer of the lymphatic system that is characterized by the presence of Reed-Sternberg cells. While the presentation and treatment of Hodgkin lymphoma differ from follicular lymphoma, both diseases can affect children and adolescents.